Are you or a loved one among the millions of people diagnosed with type 2 diabetes?  Then you may be interested in learning more about type 2 diabetes research happening at Novartis.

When you have type 2 diabetes, the body does not respond correctly to insulin. This is called insulin resistance. Insulin resistance means that fat, liver, and muscle cells do not respond normally to insulin. As a result, blood sugar does not get into cells to be stored for energy. When sugar cannot enter cells, abnormally high levels of sugar build up in the blood. This is called hyperglycemia. High levels of blood sugar often trigger the pancreas to produce more and more insulin, but it is  not enough to keep up with the body's demand.(1)

Diabetes can lead to serious complications, such as blindness, kidney damage, cardiovascular disease, nervous system disease, lower-limb amputations, and many other conditions, when not treated properly.(2)

Developing new medicines to treat diabetes is a long and complex process, but an essential one in finding new and innovative treatments.  In our quest to find new treatments, Novartis will be conducting several clinical trials for patients diagnosed with diabetes.

---

CACZ885I2207 Type 2 Diabetes Clinical Trial (Currently Enrolling) This phase 2 clinical trial will research the effectiveness of a study drug in patients with impaired glucose tolerance or type II diabetes. This study drug is an investigational drug, which means it is being tested and is not approved for the treatment of people with Impaired Glucose Tolerance or Type II Diabetes in the United States by the U.S. Food and Drug Administration (FDA). You may be eligible for this study if you: Are between the ages of 18 and 74 Are you currently suffering from Impaired Glucose Tolerance (pre-diabetes) Type 2 Diabetes Are you pregnant or nursing
CLAF237A23138 Type 2 Diabetes Clinical Trial (Currently Enrolling) The purpose of this clinical study is to determine if the study drug is safe to lower blood sugar in participants with diabetic nephropathy. Diabetic Nephropathy is a term used to describe kidney disease that occurs as a result of diabetes. This study drug is an investigational drug, which means it is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA). You may be eligible for this study if you: Are between the ages of 18 and 86 Have been diagnosed with Type 2 Diabetes Are you pregnant or nursing
CACZ885I2202 Type 2 Diabetes Clinical Trial (Currently Enrolling) The purpose of this study is to verify the dosage of the study drug and its effectiveness for participants who have type 2 diabetes and are currently taking or willing to begin taking metformin to treat their diabetes. A “study drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA). You may be eligible for this study if you: Are between the ages of 18 and 74 Have been diagnosed with Type 2 Diabetes Have not had any cancer, other than basal cell skin cancer, in the last 5 years